Rituximab

Generic Name: Rituximab

Brand Names: MabThera, Riabni, Rituxan, Rituxan Hycela, Ruxience, Truxima, Blitzima, Rixathon, Riximyo

Drug Type: Biotech

Chemical Formula: -

CAS Number: 174722-31-7

Unique Ingredient Identifier: 4F4X42SYQ6

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal antibody directed against the CD20 antigen found on the surface of normal and malignant B lymphocytes. The antibody is an IgG1 kappa immunoglobulin containing murine light and heavy-chain variable region sequences and human constant region sequences , . It was originally approved by the U...

Indication: Rituximab is indicated for the treatment of adult patients with relapsed or refractory, low-grade or follicular, CD20-positive, B-cell non-Hodgkin’s Lymphoma (NHL) as a single agent. Also, it is indicated for the treatment of adult patients with previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in pat...

Associated Conditions: Active, Moderate to Severe Rheumatoid Arthritis, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Non-Hodgkin's Lymphoma, Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA), Advanced Burkitt Lymphoma (BL), Advanced Burkitt-like lymphoma, Advanced Diffuse Large B-Cell Lymphoma (DLBCL), Advanced Mature B-cell type acute leukaemia, Moderate Pemphigus Vulgaris (PV), Non-progressive Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory Low Grade Non-Hodgkin's Lymphoma (NHL), Refractory follicular B-cell non-Hodgkin's lymphoma, Relapsed Low Grade Non-Hodgkin's Lymphoma (NHL), Relapsed follicular B-cell non-Hodgkin's lymphoma, Severe Pemphigus Vulgaris (PV)

Associated Therapies: -

Clinical Trials

Study for Newly Diagnosed Follicular Lymphoma Patients With a Large Tumor Burden

Phase 3

Completed

Conditions: Lymphoma

First Posted Date: 2005-08-29

Last Posted Date: 2007-07-03

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 360

Registration Number: NCT00136552

Locations: 🇧🇪
Groupe d'Etude des Lymphomes de l'adulte, Mont-Godinne, Belgium
🇫🇷
Hôpital Henri Mondor, Créteil, France
🇫🇷
Hôpital Saint Louis, Paris, France

and more 2 locations

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Phase 3

Terminated

Conditions: Lymphoma, Large-Cell, Diffuse

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vindesine
Drug: Vincristine
Drug: Bleomycin
Drug: Prednisone

First Posted Date: 2005-08-26

Last Posted Date: 2018-08-23

Lead Sponsor: Lymphoma Study Association

Target Recruit Count: 138

Registration Number: NCT00135499

Locations: 🇫🇷
Centre Hospitalier Robert Debré, Reims, France
🇨🇭
Schweirische Arbeitsgruppe fur klinische Krebsforschung, Lausanne, Switzerland
🇧🇪
Groupe d'Etude des Lymphomes de l'adulte, Yvoir, Belgium

and more 5 locations

Rituximab in the Treatment of HIV Associated Multicentric Castleman Disease Dependent on Chemotherapy

Phase 2

Terminated

Conditions: HIV Infections
Giant Lymph Node Hyperplasia

First Posted Date: 2005-08-08

Last Posted Date: 2007-01-12

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 25

Registration Number: NCT00127569

Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma

Phase 2

Terminated

Conditions: Burkitt Lymphoma
Non-Hodgkins Lymphoma
Atypical Burkitt Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Methotrexate
Drug: Leucovorin
Drug: Cytarabine
Drug: Ifosfamide
Drug: Etoposide
Drug: Mesna

First Posted Date: 2005-08-03

Last Posted Date: 2013-05-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00126191

Locations: 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Efficacy of Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) in Patients With HIV Associated Non-Hodgkin's Lymphoma

Phase 2

Terminated

Conditions: AIDS Related Lymphoma

First Posted Date: 2005-08-03

Last Posted Date: 2005-08-17

Lead Sponsor: French National Agency for Research on AIDS and Viral Hepatitis

Target Recruit Count: 60

Registration Number: NCT00126243

Locations: 🇫🇷
Service de Medecine Interne Hopital Antoine Beclere, Clamart, France

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Phase 2

Completed

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Fludarabine
Drug: Mitoxantrone
Drug: Rituximab
Drug: Zevalin

First Posted Date: 2005-07-14

Last Posted Date: 2014-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT00119730

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin
MALT Lymphoma

Interventions: Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2005-07-04

Last Posted Date: 2016-08-01

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 26

Registration Number: NCT00117156

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
University of Rochester Cancer Center, Rochester, New York, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 1 locations

Radiotherapy Versus Radiotherapy Plus Chemotherapy in Early Stage Follicular Lymphoma

Phase 3

Completed

Conditions: Follicular Lymphoma

Interventions: Drug: Cyclophosphamide
Radiation: Radiotherapy
Drug: Vincristine
Drug: Prednisolone
Drug: Rituximab

First Posted Date: 2005-06-24

Last Posted Date: 2022-11-18

Lead Sponsor: Trans Tasman Radiation Oncology Group

Target Recruit Count: 150

Registration Number: NCT00115700

Locations: 🇳🇿
Wellington Hospital, Wellington, New Zealand
🇦🇺
Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺
The Canberra Hospital, Garran, Australian Capital Territory, Australia

and more 18 locations

Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM)

Phase 2

Completed

Conditions: Juvenile Dermatomyositis
Dermatomyositis
Polymyositis
Myositis

Interventions: Drug: Rituximab
Drug: Placebo

First Posted Date: 2005-03-22

Last Posted Date: 2015-03-04

Lead Sponsor: University of Pittsburgh

Target Recruit Count: 200

Registration Number: NCT00106184

Locations: 🇺🇸
Cedars-Sinai Medical Center (Adult Site), Los Angeles, California, United States
🇺🇸
Stanford University (Adult Site), Stanford, California, United States
🇺🇸
Beth Israel Deaconess Medical Center (Adult Site), Boston, Massachusetts, United States

and more 28 locations

Anti-CD20 Antibody Therapy for Sjogren's Syndrome

Phase 1

Completed

Conditions: Sjogren's Syndrome

Interventions: Drug: Rituximab

First Posted Date: 2005-01-14

Last Posted Date: 2017-10-20

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 12

Registration Number: NCT00101829

Locations: 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy